CDX-0158
/ Celldex
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 13, 2019
CDX-0159, AN ANTI-KIT MONOCLONAL ANTIBODY, AS A MODULATOR OF MAST CELL-RELATED DISEASES
(ACAAI 2019)
- "Conclusion Data for CDX-0159 are consistent with improved safety and pharmacokinetic profiles. KIT inhibition with CDX-0159 or CDX-0158 decreases MC activity, supporting development of CDX-0159 in mast cell-related diseases."
Tryptase
June 13, 2019
A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=28; Completed; Sponsor: Celldex Therapeutics; Active, not recruiting ➔ Completed
Clinical • Trial completion
1 to 2
Of
2
Go to page
1